Author(s)

Fuxia Xie, Mengdan Li, Xingguo Jing^*

Department of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Immune checkpoint inhibitors (ICIs), targeting programmed cell death protein-1 (PD-1) and its ligand (PD-L1), have changed the treatment history of lung cancer, especially in the field of non-small cell lung cancer (NSCLC). ¹⁸F-FDG PET/CT, as a noninvasive and effective examination technique, reflects the location and functional information of tumor lesions through the metabolic level of glucose. Studies have shown that PD-L1 may affect the sugar metabolism of tumor cells. Therefore, ¹⁸F-FDG PET/CT can be used to predict the expression of PD-L1 and evaluate the efficacy of immunotherapy. This article mainly introduces the relationship between PD-L1 expression and NSCLC, the advantages of ¹⁸F-FDG PET/CT, the imaging mechanism of ¹⁸F-FDG PET/CT based on PD-L1 and its research progress in NSCLC, and the role of ¹⁸F-FDG PET/CT in the response and efficacy evaluation of immunotherapy in NSCLC, aiming to provide a reference for the clinic.

¹⁸F-FDG PET/CT, PD-L1, Immune Checkpoint Inhibitors, Non-Small Cell Lung Cancer, Immunotherapy

Xie, F. , Li, M. and Jing, X. (2023) Value of 18F-FDG PET/CT Based on PD-L1 to Predict Outcomes of Immunotherapy in NSCLC. Advances in Bioscience and Biotechnology, 14, 151-161. doi: 10.4236/abb.2023.144010.